Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on March 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards total options to purchase 789 shares and 6,882 RSUs, with options priced at $432.00 (closing price on grant date) and time‑based vesting over four years subject to continued employment.

CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 789 shares of Madrigal’s common stock, and in the aggregate 6,882 time-based restricted stock units. Options have an exercise price of $432.00 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity awards did Madrigal (MDGL) grant on March 1, 2026?

The company granted options to purchase 789 shares and 6,882 RSUs to 20 new non-executive employees. According to Madrigal, awards were issued as inducement grants under the 2025 Inducement Plan and approved under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and valuation context for the MDGL options granted March 1, 2026?

Options have an exercise price of $432.00 per share, equal to the closing stock price on the grant date. According to Madrigal, the exercise price matches the March 1, 2026 closing price used for grant pricing.

How do the MDGL options vest for employees granted awards on March 1, 2026?

Options vest 25% after one year, then 6.25% each quarterly anniversary thereafter. According to Madrigal, vesting is time‑based and contingent on each employee's continued employment at each vesting date.

What is the vesting schedule for the MDGL restricted stock units granted March 1, 2026?

All restricted stock units vest in four equal annual installments on the first through fourth anniversaries of the grant date. According to Madrigal, RSU vesting is time‑based and subject to continued employment at each anniversary.

Why did Madrigal (MDGL) grant inducement awards on March 1, 2026?

The awards were granted as inducement material to employees' acceptance of employment with the company. According to Madrigal, grants were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).